Magneto-Mechanical Nanotherapy for Adiposopathy: Targeting Lipid Metabolism and Inflammation

preprint OA: closed CC-BY-4.0
📄 Open PDF Full text JSON View at publisher

Abstract

not-yet-known not-yet-known not-yet-known unknown Obesity has reached critical levels worldwide, driving comorbidities like type 2 diabetes, hypertension, dyslipidemia, and cardiovascular diseases. These conditions stem from adiposopathy, a pathological alteration of adipose tissue caused by hypercaloric diets and sedentary lifestyles. Current treatments, including pharmacotherapy and bariatric surgery, are limited by side effects, invasiveness, and poor patient compliance, highlighting the urgent need for alternative therapies targeting adiposopathy. In this study, we explore a novel magneto-mechanical treatment (MMT) using functionalized magnetic nanoparticles (MNPs) to induce mechanical stress in adipose tissue cells via a low-frequency alternating magnetic field (LF-AMF). We synthesized octahedral Fe3O4 MNPs through thermal decomposition and functionalized them with meso-2,3-dimercaptosuccinic acid (DMSA) and chitosan (CHITO) to enhance biocompatibility. The effects of MMT were evaluated on macrophages and adipocytes—key players in adiposopathy—using a custom-built LF-AMF device operating below 100 Hz. We demonstrate that MMT induces cellular damage in macrophages, reactive oxygen species (ROS) production, and inhibited cell proliferation and inflammation. In adipocytes, MMT promotes lipolysis, reducing fat storage and restoring physiological differentiation. These results suggest that MMT can modulate adipose tissue composition and function, offering a promising non-invasive approach to treating adiposopathy. Further studies are needed to elucidate the molecular mechanisms and optimize therapeutic application.
Full text 2,703 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

not-yet-known not-yet-known not-yet-known unknown Obesity has reached critical levels worldwide, driving comorbidities like type 2 diabetes, hypertension, dyslipidemia, and cardiovascular diseases. These conditions stem from adiposopathy, a pathological alteration of adipose tissue caused by hypercaloric diets and sedentary lifestyles. Current treatments, including pharmacotherapy and bariatric surgery, are limited by side effects, invasiveness, and poor patient compliance, highlighting the urgent need for alternative therapies targeting adiposopathy. In this study, we explore a novel magneto-mechanical treatment (MMT) using functionalized magnetic nanoparticles (MNPs) to induce mechanical stress in adipose tissue cells via a low-frequency alternating magnetic field (LF-AMF). We synthesized octahedral Fe3O4 MNPs through thermal decomposition and functionalized them with meso-2,3-dimercaptosuccinic acid (DMSA) and chitosan (CHITO) to enhance biocompatibility. The effects of MMT were evaluated on macrophages and adipocytes—key players in adiposopathy—using a custom-built LF-AMF device operating below 100 Hz. We demonstrate that MMT induces cellular damage in macrophages, reactive oxygen species (ROS) production, and inhibited cell proliferation and inflammation. In adipocytes, MMT promotes lipolysis, reducing fat storage and restoring physiological differentiation. These results suggest that MMT can modulate adipose tissue composition and function, offering a promising non-invasive approach to treating adiposopathy. Further studies are needed to elucidate the molecular mechanisms and optimize therapeutic application. Supplementary Material File (ahm manuscript.docx) - Download - 22.57 MB Information & Authors Information Version history Copyright This work is licensed under a Non Exclusive No Reuse License.

Keywords

Authors Metrics & Citations Metrics Article Usage 316views 134downloads Citations Download citation Anna Laurenzana, Martin Albino, Giorgia Papini, et al. Magneto-Mechanical Nanotherapy for Adiposopathy: Targeting Lipid Metabolism and Inflammation. Authorea. 03 June 2025. DOI: https://doi.org/10.22541/au.174893059.92149721/v1 DOI: https://doi.org/10.22541/au.174893059.92149721/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-06-05T02:00:03.366016+00:00
License: CC-BY-4.0